Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Antares Pharma stock

Own Antares Pharma stock in just a few minutes.

Antares Pharma, Inc is a medical instruments & supplies business based in the US. Antares Pharma shares (ATRS) are listed on the NASDAQ and all prices are listed in US Dollars. Antares Pharma employs 185 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Antares Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ATRS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Antares Pharma share price

Use our graph to track the performance of ATRS stocks over time.

Antares Pharma shares at a glance

Information last updated 2021-04-30.
52-week range$2.39 - $5.07
50-day moving average $4.10
200-day moving average $3.84
Wall St. target price$6.42
PE ratio 11.4848
Dividend yield N/A (0%)
Earnings per share (TTM) $0.33

Buy Antares Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Antares Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Antares Pharma under- or over-valued?

Valuing Antares Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Antares Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Antares Pharma's P/E ratio

Antares Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Antares Pharma shares trade at around 11x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Antares Pharma's EBITDA

Antares Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.2 million.

The EBITDA is a measure of a Antares Pharma's overall financial performance and is widely used to measure a its profitability.

Antares Pharma financials

Revenue TTM $149.6 million
Operating margin TTM 9.1%
Gross profit TTM $86.5 million
Return on assets TTM 4.93%
Return on equity TTM 64.74%
Profit margin 37.57%
Book value $0.71
Market capitalisation $639.7 million

TTM: trailing 12 months

Shorting Antares Pharma shares

There are currently 5.6 million Antares Pharma shares held short by investors – that's known as Antares Pharma's "short interest". This figure is 14.4% up from 4.9 million last month.

There are a few different ways that this level of interest in shorting Antares Pharma shares can be evaluated.

Antares Pharma's "short interest ratio" (SIR)

Antares Pharma's "short interest ratio" (SIR) is the quantity of Antares Pharma shares currently shorted divided by the average quantity of Antares Pharma shares traded daily (recently around 881516.5615142). Antares Pharma's SIR currently stands at 6.34. In other words for every 100,000 Antares Pharma shares traded daily on the market, roughly 6340 shares are currently held short.

However Antares Pharma's short interest can also be evaluated against the total number of Antares Pharma shares, or, against the total number of tradable Antares Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Antares Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Antares Pharma shares in existence, roughly 30 shares are currently held short) or 0.0338% of the tradable shares (for every 100,000 tradable Antares Pharma shares, roughly 34 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Antares Pharma.

Find out more about how you can short Antares Pharma stock.

Antares Pharma share dividends

We're not expecting Antares Pharma to pay a dividend over the next 12 months.

Have Antares Pharma's shares ever split?

Antares Pharma's shares were split on a 1:5 basis on 28 January 1999. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Antares Pharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Antares Pharma shares which in turn could have impacted Antares Pharma's share price.

Antares Pharma share price volatility

Over the last 12 months, Antares Pharma's shares have ranged in value from as little as $2.39 up to $5.07. A popular way to gauge a stock's volatility is its "beta".

ATRS.US volatility(beta: 1.48)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Antares Pharma's is 1.4843. This would suggest that Antares Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Antares Pharma overview

Antares Pharma, Inc. , a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site